I’m an obesity expert and can’t wait for the compounding craze to stop

Written and edited by the WorldPing NewsdeskPublished Sat, 03 Oct 2026 11:30:00 UTCUpdated Sat, 03 Oct 2026 11:30:00 UTCOriginal reporting: Fortune

What happened

If you can't name the medical reason your patient needs a knockoff GLP-1, you don't have one.

Key facts

If you can't name the medical reason your patient needs a knockoff GLP-1, you don't have one.
Reported by Fortune and published Sat, 03 Oct 2026 11:30:00 UTC.

Why it matters

Economic releases and corporate results feed directly into rate expectations, currency moves and equity pricing, so the detail here often matters more to markets than the headline itself.

What to watch next

Revisions to the initial figures once fuller data is released
How rate expectations and index futures respond
Guidance or commentary from the companies and policymakers involved

Sources

The original report was published by Fortune. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at Fortune

Related WorldPing coverage

CNBC World

WorldPing

CNBC World

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Brief by WorldPing · Original reporting by CNBC World